Clinical Cancer Research - Google Scholar Metrics

h5-index:125
h5-median:161

h5-index is the h-index for articles published in the last 5 complete years. It is the largest number h such that h articles published in 2014-2018 have at least h citations each.hide

h5-median for a publication is the median number of citations for the articles that make up its h5-index.hide

#5 Oncology

Title / Author	Cited by	Year
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical Cancer Research 20 (19), 5064-5074	1320	2014
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA GR Oxnard, CP Paweletz, Y Kuang, SL Mach, A O'Connell, MM Messineo, ... Clinical Cancer Research 20 (6), 1698-1705	508	2014
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas KP Pennington, T Walsh, MI Harrell, MK Lee, CC Pennil, MH Rendi, ... Clinical Cancer Research 20 (3), 764-775	391	2014
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer MD Burstein, A Tsimelzon, GM Poage, KR Covington, A Contreras, ... Clinical Cancer Research 21 (7), 1688-1698	349	2015
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical Cancer Research 22 (18), 4585-4593	332	2016
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response PF Robbins, SH Kassim, TLN Tran, JS Crystal, RA Morgan, SA Feldman, ... Clinical Cancer Research 21 (5), 1019-1027	331	2015
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928	312	2017
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical Cancer Research 20 (7), 1757-1767	307	2014
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas TY Seiwert, Z Zuo, MK Keck, A Khattri, CS Pedamallu, T Stricker, C Brown, ... Clinical Cancer Research 21 (3), 632-641	303	2015
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ... Clinical Cancer Research 20 (10), 2773-2782	290	2014
TGF-β–Induced Upregulation of malat1 Promotes Bladder Cancer Metastasis by Associating with suz12 Y Fan, B Shen, M Tan, X Mu, Y Qin, F Zhang, Y Liu Clinical Cancer Research 20 (6), 1531-1541	277	2014
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design JM Llovet, V Hernandez-Gea Clinical Cancer Research 20 (8), 2072-2079	272	2014
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical Cancer Research 20 (7), 1965-1977	272	2014
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors DA Wainwright, AL Chang, M Dey, IV Balyasnikova, CK Kim, A Tobias, ... Clinical Cancer Research 20 (20), 5290-5301	269	2014
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ... Clinical Cancer Research 21 (19), 4286-4293	268	2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes M Freeman-Keller, Y Kim, H Cronin, A Richards, G Gibney, JS Weber Clinical Cancer Research 22 (4), 886-894	262	2016
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong, J Sandoval-Tan, G Ladrera, ... Clinical Cancer Research 21 (14), 3196-3203	261	2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ... Clinical Cancer Research 21 (10), 2315-2324	251	2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy G Kim, G Ison, AE McKee, H Zhang, S Tang, T Gwise, R Sridhara, E Lee, ... Clinical Cancer Research 21 (19), 4257-4261	248	2015
Microsatellite Instability as a Biomarker for PD-1 Blockade JC Dudley, MT Lin, DT Le, JR Eshleman Clinical Cancer Research 22 (4), 813-820	234	2016

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.